Related Experiment Video
Updated: May 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Childhood leukemia]
Olli Lohi1, Jukka Kanerva, Mervi Taskinen
1TAYS, lastenklinikka.
Insights
Childhood leukemia, primarily acute lymphoblastic leukemia, now has an 80-90% recovery rate. Research focuses on improving treatments for poor-prognosis cases and reducing therapy for those with good outcomes.
Area of Science:
- Pediatric Hematology/Oncology
- Cancer Research
- Leukemia Pathophysiology
Context:
- Childhood leukemia represents a significant oncological challenge.
- Acute lymphoblastic leukemia (ALL) is the most common type in children.
- Chronic leukemias are rare or not observed in pediatric populations.
Purpose:
- To summarize the current landscape of childhood leukemia.
- To highlight the improved prognosis for common leukemia types.
- To identify future research directions in pediatric leukemia treatment.
Summary:
- Childhood leukemia predominantly includes acute lymphoblastic leukemia (ALL) and a smaller fraction of acute myelogenous leukemia (AML).
- Chronic myelogenous leukemia (CML) is rare in children, and chronic lymphocytic leukemia (CLL) is not typically encountered.
- Prognosis has significantly improved, with recovery rates of 80-90% for lymphocytic leukemia and 60-70% for myelogenous leukemia.
Impact:
- Improved survival rates for childhood leukemia underscore advances in pediatric oncology.
- Future research aims to refine treatments for high-risk leukemia groups.
- Efforts are underway to develop less intensive therapies for leukemia patients with favorable prognoses.
Abstract:
Most cases of childhood leukemia are acute lymphoblastic leukemia, a small proportion being myelogenous leukemia. Chronic myelogenous leukemia is rare in children, whereas chronic lymphocytic leukemia is not encountered. The prognosis of childhood leukemia has improved considerably so that approximately 80 to 90% of those having lymphocytic leukemia and 60 to 70% of those having myelogenous leukemia will recover fully. The challenge is to develop new treatments for disease groups having a poor prognosis and on the other hand to lighten the treatments for leukemias having a good prognosis.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells
Pharmacokinetics in Pediatric Patients: Drug Excretion
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...

